EPA + DHA in SMEDS Formulation
Dietary SupplementA single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
NCT Number: NCT03443076
This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation compared with a standard omega-3-acid ethyl ester product in healthy men and women.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Not applicable
MB Clinical Research, LLC, Boca Raton, Florida, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A single dose of 500 mg EPA + DHA administered in a self-micro-emulsifying delivery system (SMEDS) formulation
A single dose of 840 mg EPA + DHA administered as Lovaza. This intervention was used as an active comparator in this study. Lovaza was already FDA-approved when the study was conducted.
Time frame: 0-24 h on Days 0-1 and on Days 14-15
Midwest Center for Metabolic and Cardiovascular Research
Other
A Randomized, Crossover Study to Assess the Relative Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid in a Self-micro-emulsifying Delivery System (SMEDS) Formulation Compared With a Standard Omega-3-acid Ethyl Ester Product
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07345130
Bioavailability, Bioequivalence
Las Vegas, Nevada, United States
View Trial DetailsNCT06481709
Bioavailability
Toronto, Ontario, Canada
View Trial DetailsNCT05263895
Bioavailability, COVID-19
New Haven, Connecticut, United States
View Trial DetailsNCT05627518
Bioavailability, Pharmacokinetics
Ljubljana, Ukmarjeva Ulica 6, Slovenia
View Trial Details